Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jan Ricar"'
Autor:
Jiri Polivka, Mohamed A. Gouda, Mahyar Sharif, Martin Pesta, Helen Huang, Inka Treskova, Vlastimil Woznica, Jindra Windrichova, Katerina Houfkova, Radek Kucera, Tomas Fikrle, Jan Ricar, Kristyna Pivovarcikova, Ondrej Topolcan, Filip Janku
Publikováno v:
Cancer Medicine, Vol 13, Iss 19, Pp n/a-n/a (2024)
ABSTRACT Background Melanoma is the most aggressive skin cancer with ability to recur also after early‐stage tumor surgery. The aim was to identify early‐stage melanoma patients at high risk of recurrence using liquid biopsy, estimating of mutate
Externí odkaz:
https://doaj.org/article/813949faa5b140ff89864ce7b2e7fc3e
Publikováno v:
Dermatologic therapyREFERENCES. 35(6)
Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open-label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38ddc559140751cdbef3ae9535cf7353
https://pubmed.ncbi.nlm.nih.gov/35278027
https://pubmed.ncbi.nlm.nih.gov/35278027
Autor:
Denisa Kacerovska, Jan Ricar, Michal Michal, Petr Martinek, Katerina Cerna, Dmitry V. Kazakov, Petr Grossmann
Publikováno v:
The American Journal of dermatopathology. 34(6)
Muir-Torre syndrome (MTS), a phenotypic variant of the more common hereditary nonpolyposis colorectal cancer syndrome, or Lynch syndrome, is an autosomal dominantly inherited condition that combines at least one cutaneous sebaceous neoplasm and at le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8515692d5f17fa5fd8226e7c167ed8b
https://pubmed.ncbi.nlm.nih.gov/22814321
https://pubmed.ncbi.nlm.nih.gov/22814321
Publikováno v:
International Journal of Dermatology. 52:1620-1621
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1552685f81fa0f73c05c00cee6e8265
https://doi.org/10.1111/j.1365-4632.2011.05410.x
https://doi.org/10.1111/j.1365-4632.2011.05410.x
Autor:
Miloš Pešek, Marek Minarik, Jindrich Finek, Jana Krejčí, Zbynek Bortlicek, Lucie Benesova, Jan Ricar, Ondrej Fiala
Publikováno v:
Lung Cancer. 77:S30
Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used in treatment of advanced NSCLC. Patients harboring EGFR or KRAS mutations represent minority of all patients in caucasian population and there is no available predictor f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6582cf5bcdaf3a2c36186097efbc985
https://doi.org/10.1016/j.lungcan.2012.05.055
https://doi.org/10.1016/j.lungcan.2012.05.055
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.